Moderna shares are trading higher after vaccine makers said COVID shots for the JN.1 variant neutralize newer strains. The FDA will also vote on vaccine recommendations for 2024-2025.
Portfolio Pulse from Benzinga Newsdesk
Moderna shares are trading higher after the company announced that its COVID-19 vaccine for the JN.1 variant neutralizes newer strains. Additionally, the FDA will vote on vaccine recommendations for 2024-2025.
June 05, 2024 | 6:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna shares are trading higher after the company announced that its COVID-19 vaccine for the JN.1 variant neutralizes newer strains. The FDA's upcoming vote on vaccine recommendations for 2024-2025 adds further positive sentiment.
The announcement that Moderna's vaccine neutralizes newer strains is a significant positive development, likely boosting investor confidence. The upcoming FDA vote on vaccine recommendations for 2024-2025 adds further potential for positive regulatory news.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100